SecBot SecBot
F-1/A ·Filed Nov 9, 2026
WW

WWB

WINDWARD BIO GROUP AG
NEUTRAL
Impact 5/10
Horizonimmediate Processed7d 18h ago SEC0001193125-26-452536
Foreign IPO amendment
Actionable Insight • Neutral

Monitor the final IPO pricing and the Nasdaq listing approval. The concurrent Sanofi private placement provides a strategic endorsement. Key catalysts are the Phase 2 primary results for WIN378 in asthma (1H 2027) and full Phase 1 results for WIN027 (1H 2027).

DirectionNeutral
Confidencehigh
Horizonimmediate

Executive Summary

Windward Bio Group AG, a Swiss clinical-stage biotech, filed Amendment No. 2 to its F-1 registration statement for an IPO of 10,294,117 common shares on Nasdaq (symbol WWB) at an estimated price range of $16.00-$18.00 per share. The filing also discloses a concurrent $50 million private placement with Sanofi for common shares and pre-funded warrants. The company is developing ultra-long-acting antibody therapies for respiratory and dermatologic diseases, with lead candidates WIN378 (anti-TSLP) and WIN027 (anti-TSLP/IL-13 bispecific).

Key Financial Metrics

Price Range
$16.00-$18.00 per share

Key Facts

  • IPO of 10,294,117 common shares at estimated $16.00-$18.00 per share on Nasdaq under symbol WWB.
  • Concurrent private placement with Sanofi for $50.0 million: 1,532,691 common shares and pre-funded warrants for 1,408,485 shares at IPO price.
  • Underwriters granted option to purchase up to 1,544,117 additional shares.
  • Estimated net proceeds of $203.8 million from IPO and private placement ($228.0 million if overallotment exercised).
  • Pro forma as adjusted cash, cash equivalents and marketable securities of $411.1 million as of June 30, 2026.
  • Net loss of $42.6 million for six months ended June 30, 2026; accumulated losses of $93.2 million.
  • Cash, cash equivalents and marketable securities of $207.3 million as of June 30, 2026.
  • Lead candidates: WIN378 (anti-TSLP, Phase 2/3 in asthma, Phase 2 in COPD) and WIN027 (anti-TSLP/IL-13 bispecific, Phase 1).
  • Proceeds to fund WIN378 and WIN027 clinical programs, bispecific IND-enabling studies, and working capital into first half of 2029.
  • Series B investors waived $55.0 million second tranche commitment on October 30, 2026.

Financial Impact

Estimated net proceeds of $203.8 million from IPO and concurrent private placement, increasing pro forma as adjusted cash to $411.1 million.

cashequitydilution

Risk Factors

  • Clinical-stage biotech with no approved products or revenue; history of significant losses.
  • Dependence on successful clinical development and regulatory approval of WIN378 and WIN027.
  • Reliance on third-party manufacturers and licensors in China (Kelun, HBM, Qyuns) with associated geopolitical and supply chain risks.
  • Substantial milestone and royalty obligations under license agreements.
  • Swiss corporate structure with different shareholder rights and limited U.S. investor protections.
  • No prior public market for shares; price volatility expected.

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
F-1/A Filing (Primary)0001193125-26-452536
Document: d111653dex32.htm0001193125-26-452536
Document: d111653dex11.htm0001193125-26-452536

US Market Status

Market Closed · Opens in 8h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026